Minimizing the risk of posttransplant malignancy

Area of Science:

• Immunology
• Oncology
• Transplant Medicine

Background:

• Immunosuppressive therapies improve transplant survival but increase risks of cardiovascular disease and malignancy.
• Transplant recipients are immunocompromised, heightening susceptibility to oncovirus activity and specific tumor types.
• Some immunosuppressants, like calcineurin inhibitors (CNIs), may have direct oncogenic effects, promoting tumor growth and metastasis.

Purpose of the Study:

• To evaluate the impact of mTOR inhibitors versus CNIs on malignancy incidence in transplant patients.
• To assess the potential of sirolimus-based, CNI-free regimens in reducing post-transplant cancer risk.

Main Methods:

• Analysis of United Network for Organ Sharing (UNOS) data comparing mTOR inhibitor use with or without CNIs.
• Review of the Rapamune Maintenance Regimen study outcomes for sirolimus-based, CNI-free therapy.
• Examination of the CONVERT study data comparing sirolimus conversion to continued CNI-based therapy.

Main Results:

• UNOS data indicated reduced tumor incidence with mTOR inhibitors, irrespective of CNI co-administration.
• The Rapamune Maintenance Regimen study showed lower malignancy incidence at 5 years with sirolimus-based, CNI-free therapy post-CsA withdrawal.
• The CONVERT study found significantly lower malignancy rates (3.1%) in patients converted to sirolimus compared to those on CNI-based therapy (9.8%).

Conclusions:

• mTOR inhibitors demonstrate anti-tumoral and anti-angiogenic properties, associated with reduced malignancy incidence.
• Eliminating CNIs and introducing sirolimus may play a crucial role in mitigating cancer risk in post-transplant patients.
• Sirolimus-based, CNI-free immunosuppression presents a promising strategy for reducing long-term cancer risk in organ transplant recipients.